Fairmount Funds Management’s POINT Biopharma Global Inc. Common Stock PNT Stock Holding History

Fairmount Funds Management’s Portfolio PNT Stock Details PNT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-2,833,950	Closed	-$21.9M	–	27
2022 Q3	$21.9M	Buy	2,833,950 +1,000,000	+55%	+$8.49M	3.85%	13
2022 Q2	$12.5M	Sell	1,833,950 -478,573	-21%	-$3.66M	2.86%	13
2022 Q1	$18.4M	Buy	2,312,523 +793,141	+52%	+$5.04M	4.36%	10
2021 Q4	$8.51M	Buy	1,519,382 +419,893	+38%	+$3.15M	2.81%	13
2021 Q3	$8.46M	Buy	1,099,489 +235,275	+27%	+$2.15M	3.07%	14
2021 Q2	$8.88M	Buy	864,214 +814,214	+1,628%	+$8.28M	3.65%	11
2021 Q1	$526K	Buy	+50,000	New	+$678K	0.22%	20

Other funds holding PNT

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

PHS

PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

SCM

Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return

GPP

Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

Fairmount Funds Management's PNT Position: Q4 2022 in Review

Fairmount Funds Management sold out of POINT Biopharma Global Inc. Common Stock (PNT) in Q4 2022, closing a stake of 2,833,950 shares — an estimated $21.9M sold.

Fairmount Funds Management first reported a position in PNT in Q1 2021 and held it in 7 quarters. The position peaked at $21.9M in Q3 2022. 109 funds tracked by Wall St. Rank hold PNT as of Q4 2022.

Fairmount Funds Management reported no remaining POINT Biopharma Global Inc. Common Stock position as of Q4 2022 after selling out during the quarter.
Fairmount Funds Management sold 2,833,950 POINT Biopharma Global Inc. Common Stock shares in Q4 2022, an estimated $21.9M.
Fairmount Funds Management first reported a position in POINT Biopharma Global Inc. Common Stock in Q1 2021 and held it in 7 quarters.
Fairmount Funds Management's POINT Biopharma Global Inc. Common Stock position peaked at $21.9M in Q3 2022.
109 funds tracked by Wall St. Rank held POINT Biopharma Global Inc. Common Stock as of Q4 2022.

Based on Fairmount Funds Management's 13F filing for Q4 2022, filed 14 Feb 2023.